* Please note that the following agenda timings are Eastern Standard Time.  


8:30 am
Join us for a coffee morning to meet your peers ahead of the conference

8:45 am Chair’s Opening Remarks

TGF-β in Immuno-Oncology: The Story So Far

9:00 am The Role of TGF-β in the Tumor Ecosystem & Immunotherapy

9:30 am An Overview of the TGF-β IO Market

10:00 am
Morning Networking Break


Meet and connect with your peers in this dedicated networking session.

Preclinical Track

Moving Beyond the Challenges of Preclinical Tumor Models

10:30 am Preclinical Models Reveal Heterogeneous Responses to TGF-β Antagonism & Highlight Potential Sites of Off-Tumor Toxicities

11:00 am Inhibition of Integrin αvβ8 in Combination with Low Dose Radiation Induces Antitumor Effect in Advanced Immune Checkpoint Blockade Refractory Tumor Model

11:30 am Therapeutic Inhibition of TGF-β Mediated Immune Suppression

Clinical Track

The Latest Clinical Advances

10:30 am BCA101, A Novel Dual-Action Antibody Combining the Precision Targeting of EGFR with the Immunomodulating Power of TGF-β

  • Rachel Salazar Vice President, Head of Programs & Portfolio, Bicara Therapeutics

11:00 am Clinical Update on TST005

11:30 am Bintrafusp Afla: What, Why & How?

  • Julius Strauss Co-Director Laboratory of Tumor Immunology & Biology, Center of Cancer Research, NCI, NIH

12:00 pm Networking Lunch

Novel Insights into Mechanisms of TGF-β Regulators

12:30 pm Impact of Dual TGF-β/PD-L1 Therapeutic Blockade on CD8 T Cell Phenotypes

1:00 pm How to Design Targetable Forms of TGF-β

  • Yuti Chernajovsky Emeritus Professor of Molecular Medicine, Queen Mary University of London

1:30 pm Roundtable Discussion

Exploring the Clinical Landscape

12:30 pm Understanding the TGF-β Landscape

1:00 pm Optimizing Clinical Studies to Evaluate Safety & Tolerability

1:30 pm Roundtable Discussion

2:00 pm
Afternoon Networking Break & Poster Session


This scientific poster session is an opportunity to present your latest data and innovation. Submit your poster on the website in and share your breakthroughs with your peers.

Elevating Innovative Approaches to Regulation of TGF-β

2:30 pm Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus

  • Steve Thorne Chief Scientific Officer, Kalivir Immunotherapuetics

3:00 pm Targeting Autotaxin – A Novel Approach to Interrupt TGF-β-Mediated Pathology

3:30 pm Discover the Potential of Integrin Inhibitors to Selectively Block TGF-β

  • Stephen Nishimura Professor & Chief of Pathology, University of California San Francisco

4:00 pm Chair’s Closing Remarks

4:10 pm End of Day One